Artia Global Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Artia Global Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-219,719	Closed	-$29M	–	49
2025 Q1	$29M	Hold	219,719	–	–	7.34%	5
2024 Q4	$18.4M	Buy	219,719 +3,200	+1%	+$263K	6.56%	3
2024 Q3	$15.8M	Hold	216,519	–	–	4.32%	4
2024 Q2	$14.8M	Buy	216,519 +6,423	+3%	+$445K	2.87%	8
2024 Q1	$14.5M	Buy	210,096 +168,496	+405%	+$11.6M	2.92%	7
2023 Q4	$2.98M	Hold	41,600	–	–	0.87%	13
2023 Q3	$2.17M	Hold	41,600	–	–	0.9%	17
2023 Q2	$2.63M	Hold	41,600	–	–	0.91%	25
2023 Q1	$2.25M	Hold	41,600	–	–	0.83%	21
2022 Q4	$2.2M	Buy	+41,600	New	+$2.08M	0.84%	18

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Artia Global Partners's ITCI Position: Q2 2025 in Review

Artia Global Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 219,719 shares — an estimated $29M sold.

Artia Global Partners first reported a position in ITCI in Q4 2022 and held it in 10 quarters. The position peaked at $29M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Artia Global Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Artia Global Partners sold 219,719 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $29M.
Artia Global Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 10 quarters.
Artia Global Partners's Intra-Cellular Therapies Inc. position peaked at $29M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Artia Global Partners's 13F filing for Q2 2025, filed 14 Aug 2025.